[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
10-Dec-2012

[ | E-mail ] Share Share

Contact: Michelle Martella
mmartella@wiley.com
201-748-6145
Wiley

Devalued and distrusted: Can the pharmaceutical industry restore its broken image?

Offers a balanced view of the role of drug discovery in improving public health

Devalued and Distrusted: Can the Pharmaceutical Industry Restore Its Broken Image? offers a balanced view of the role of drug discovery in improving public health.

The author, former Pfizer president John LaMattina addresses the progress that industry has made in improving its abilities to measure both risk and benefits of its new medicines, and then tackles the issue of R&D productivity -- the reasons for the drop-off, and how the industry can rehabilitate its image.

Devalued and Distrusted is intended to provide patients, physicians, regulators, and payers with an appreciation of these issues as well as the value that pharmaceutical R&D adds to society.

###

Devalued and Distrusted: Can the Pharmaceutical Industry Restore Its Broken Image?
December 2012, 128pp
978-1-1184-8747-1
$22.95; CAN $32.95; €24.60; £20.25

To arrange an interview with John L. LaMattina or for a review copy please contact: Michelle Martella.

About the Author

John L. LaMattina, PhD, retired as president of Pfizer Global Research and Development in 2007 where he managed more than 13,000 scientists and support professionals in the United States, Europe and Asia. Dr. LaMattina has received numerous awards including an Honorary Doctor of Science degree from the University of New Hampshire. He is the author of a number of publications including the book Drug Truths: Dispelling the Myths About Pharma R & D published by Wiley in 2008. He also is a contributor to Forbes.com with his Drug Truths blog.

"LaMattina stands out from many of the other observers of the industry." (Nature Chemistry, May 2009)

CONTENTS

Introduction

Part 1. "The 4 Secrets That Drug Companies Don't Want You to Know"

Part 2. What Has Happened to R&D Productivity?

a. Impact of Mergers

b. Impact of FDA

c. Impact of Payers

Part 3. Challenges in Key Therapeutic Areas for Improving Health

a. Cancer

b. Diseases of the Brain

c. Cardiovascular Disease

d. Diabetes

e. Bacterial Infections

Part 4. Improving R&D Output

a. View of Others

b. Personal Vision

Part 5. Restoring the Pharma Image

Part 6. Final Thoughts

About Wiley

Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley is a global provider of content and content-enabled workflow solutions in areas of scientific, technical, medical, and scholarly research; professional development; and education. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.